Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiangxue Antiviral Oral Liquid is a proprietary traditional Chinese medicine (TCM) developed and marketed by Guangzhou Xiangxue Pharmaceutical. Formulated as an oral liquid, it is primarily used for its heat-clearing, dampness-removing, blood-cooling, and detoxifying properties. Clinically, it is indicated for the treatment of various viral infections, including the common cold, influenza, upper respiratory tract infections, mumps, viral conjunctivitis, and hand, foot and mouth disease (HFMD). As a TCM compound, its therapeutic effect is derived from the synergistic action of multiple herbal components rather than a single molecular target. It is recognized as a nationally protected key traditional Chinese medicine variety in China and has completed Phase 4 clinical research, confirming its status as a marketed product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiangxue Antiviral Oral Liquid.